Monitor for future software release announcements regarding PSMA-PET-MR fusion capabilities and any resulting adoption metrics at TULSA-PRO centers. This agreement is a market-development initiative, not a near-term revenue catalyst.
Price Chart
Executive Summary
Profound Medical announced a co-education agreement with Telix Pharmaceuticals to educate physicians on the complementary roles of Telix's PSMA-PET imaging and Profound's TULSA-PRO platform. The agreement also includes plans to develop PSMA-PET-MR image-fusion capabilities for a future software release. This is a non-financial commercial collaboration with no revenue or deal terms disclosed.
Key Facts
- Co-education agreement with Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) announced October 9, 2026.
- Collaboration covers educational initiatives at medical meetings, KOL programs, summits, and webinars.
- Profound is developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console (TDC) software.
- No financial terms, revenue guidance, or material quantitative data disclosed in the filing.
Financial Impact
No financial terms disclosed; collaboration is educational in nature with no revenue or cost figures provided.
Risk Factors
- Co-education agreements typically have no direct revenue impact and may not translate into accelerated commercial adoption.
- Planned software functionality is not yet released and may face development or regulatory delays.
- No financial commitment from either party disclosed, limiting near-term materiality.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006559 |
| Exhibit: exh_991.htm | 0001171843-26-006559 |
| Document: 0001171843-26-006559-index-headers.html | 0001171843-26-006559 |
| Document: 0001171843-26-006559-index.html | 0001171843-26-006559 |
| Document: 0001171843-26-006559.txt | 0001171843-26-006559 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $5.56 | awaiting T+5 | — | $5.64 (+1.53%) |
Oct 14, 2026 13d ago | 8-K | $6.62 $5.69 | ▼ −14.05% | ▼ −14.50% | $5.64 (−14.73%) |
Oct 9, 2026 18d ago | 8-K | $6.90 $6.01 | ▼ −12.90% | ▼ −10.93% | $5.64 (−18.19%) |
Oct 7, 2026 20d ago | 8-K | $6.91 $6.31 | ▼ −8.68% | ▼ −8.41% | $5.64 (−18.31%) |
Sep 3, 2026 7w ago | 8-K | $6.89 $5.81 | ▼ −15.67% | ▼ −14.47% | $5.64 (−18.07%) |
Sep 3, 2026 7w ago | 8-K | $6.80 $5.97 | ▼ −12.21% | ▼ −11.06% | $5.64 (−16.99%) |
Aug 17, 2026 10w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.64 (−13.82%) |
Aug 17, 2026 10w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.64 (−13.82%) |
Jul 24, 2026 13w ago | 8-K | $7.26 $7.25 | ▼ −0.14% | ▼ −0.51% | $5.64 (−22.25%) |
Jul 15, 2026 14w ago | 8-K | $6.96 $6.99 | ▲ +0.43% | ▲ +1.41% | $5.64 (−18.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers